Wales backs NHS use of Actelion’s Uptravi for PAH

14th June 2018 Uncategorised 0

Some patients with pulmonary arterial hypertension (PAH) are now able to access Actelion’s selexipag on the NHS in Wales after a green light from the All Wales Medicines Strategy Group (AWMSG).

More: Wales backs NHS use of Actelion’s Uptravi for PAH
Source: News